Drugs Made In America Acquisition Corp. (DMAAR) Stock Price & Analysis

Drugs Made In America Acquisition Corp. (DMAAR) fell 0.08% to USD 0.13 as of September 9, 2026 at 10:50 UTC, according to Nexqual real-time market data.

DMAAR last closed at USD 0.13; the session ranged USD 0.11–0.13 on volume of 1,244 shares. Market capitalization is —, with a 52-week range of USD 0.11–0.13 (NGM). Source: Nexqual, September 9, 2026 at 10:50 UTC.

Key Statistics (as of September 9, 2026 at 10:50 UTC)

From Drugs Made In America Acquisition Corp.'s Latest SEC 10-K Filing (filed 2026-04-15)

Key Strengths & Strategy (as disclosed to the SEC)

• Because we are able to complete our initial business combination using our cash, debt or equity securities, or a combination of the foregoing, we have the flexibility to use the most efficient combination that will allow us to tailor the consideration to be paid to the target business to fit its needs and desires.

Partnerships

• Elmasri is expected to enter into an Indemnity Agreement, a Letter Agreement and a Registration Rights Agreement with the Company on the same terms as the other directors and officers of the Company that executed similar agreements at the time of the consummation of the Company's IPO.
• The Interim Loan represents a direct financial obligation of the Company.   On March 23, 2026, the Company entered into the Investment Agreement with the Investor relating to a proposed financing transaction pursuant to which the Investor indicated its intent to provide financing to the Company through a convertible note investment, of which the Interim Loan represented the first tranche.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 10:50 UTC. This page is informational and not investment advice.